Lenti-HPV TCR-VP(VP-TCR-C197)
The ready-to-use lentiviral particles of Lenti-HPV TCR-VP is packaged using 3rd generation of lentiviral packaging system, in which the gene of Human TCR will be driven by a CMV promotor. The target gene of TCR packaged in lentiviral particles could be used for high efficency tranduction of T cells and stably integrated expression.
Specifications
Type of Therapeutics
T cell receptor
Packaging System
Lentivirus
Targeting Diseases
Cancer, HPV 16 infection, or HPV-positive premalignancy
Target
Introduction
Human papillomavirus (HPV) is a DNA virus from the papillomavirus family that is capable of infecting humans. Like all papillomaviruses, HPVs establish productive infections only in keratinocytes of the skin or mucous membranes. Most HPV infections are subclinical and will cause no physical symptoms; however, in some people subclinical infections will become clinical and may cause benign papillomas (such as warts [verrucae] or squamous cell papilloma), premalignant lesions that will drive to cancers of the cervix, vulva, vagina, penis, oropharynx and anus. In particular, HPV16 and HPV18 are known to cause around 70% of cervical cancer cases.
Alternative Names
MBP; Myelin A1 Protein; Myelin Basic Protein; Myelin Membrane Encephalitogenic Protein; TCR; T cell receptor; transgenic TCR; antigen-specific T cell receptors; Engineering T-cell receptors; recombinant t cell receptors; specific t cell receptor; modified t cell receptor; retroviral vector; Multiple sclerosis; MS
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Related Products
Viral InfectionCarcinomaOthers
Kits for CARs/TCRs Development 
Datasheet
Subscribe to Our Newsletter for Updates: